Lupin Limited said that it has launched the authorized generic version of Brovana (arformoterol tartrate) Inhalation Solution 15 mcg /2 mL, unit-dose vials, of Sunovion Pharmaceuticals, in the US.

Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL has approval in the US for the long-term, twice-daily maintenance treatment of bronchoconstriction in patients having chronic obstructive pulmonary disease (COPD).

The indication also covers patients with emphysema and chronic bronchitis. Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is to be administered only through nebulization.

Earlier this week, Lupin Limited said that its board of directors has sanctioned the plans of the Indian pharma company to foray into the digital healthcare segment with a focus to offer doctors and patients in India with a digital therapeutics platform.

Lupin Limited had recently incorporated a fully-owned subsidiary called Lupin Digital Health Limited to handle its new digital healthcare business.

  Arformoterol Tartrate, Brovana, chronic obstructive pulmonary disease, COPD, Lupin, Lupin Digital Health Limited, Sunovion Pharmaceuticals, USA